CPhI and P-MEC India sees participation of over 1500 exhibitors

40,000 visitors and representatives of more than 80 countries set to visit the show

Zydus receives final approval from USFDA for Famotidine Injection

Famotidine Injection is indicated to treat ulcers of the stomach and intestines and to prevent intestinal ulcers from coming back after they have healed

Biocon Biologics features on ASIA IP ELITE List 2022

This is the fifth consecutive year that a Biocon Group company has made it to the Asia lP ELITE list

Apollo Hospital launches Vertigo and Balance Disorder clinic in Hyderabad

Alembic Pharma gets USFDA approval for Glycopyrrolate Injection USP

This is the first injectable product approval from our General Sterile Facility (F-3) which was inspected in August, 2022.

Ajanta Pharma bags India’s "Best Managed Companies" award

For the last ten financial years, the company has posted healthy performance with its revenue from operations growing at 15% CAGR and net profit at 23% CAGR

Dupixent Phase 3 data showed significant histological remission of eosinophilic esophagitis

68% of children on a higher dose of Dupixent achieved histological disease remission at week 16

Biocon Sdn. Bhd. enters Malaysia Book of Records

The 562,000 square feet facility has been recognized as the first and largest integrated insulin manufacturer in Malaysia by MBR

Merck and Eisai provide update on Phase 3 LEAP-002 trial evaluating KEYTRUDA

The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.

Merck updates on Phase 3 Keynote-412 trial in advanced head and neck squamous cell carcinoma